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Background: Pathologic studies play an important role in evaluating patients with Alport syndrome besides
genotyping. Difficulties still exist in diagnosing Alport syndrome (AS), and misdiagnosis is a not-so-rare event, even
in adult patient evaluated with renal biopsy.
Methods: We used nested case–control study to investigate 52 patients previously misdiagnosed and 52 patients
initially diagnosed in the China Alport Syndrome Treatments and Outcomes Registry e-system.
Results: We found mesangial proliferative glomerulonephritis (MsPGN, 26.9%) and focal and segmental
glomerulosclerosis (FSGS, 19.2%) were the most common misdiagnosis. FSGS was the most frequent misdiagnosis
in female X-linked AS (fXLAS) patients (34.8%), and MsPGN in male X-linked AS (mXLAS) patients (41.2%). Previous
misdiagnosed mXLAS patients (13/17, 76.5%) and autosomal recessive AS (ARAS) patients (8/12, 66.7%) were
corrected after a second renal biopsy. While misdiagnosed fXLAS patients (18/23, 78.3%) were corrected after a
family member diagnosed (34.8%) or after rechecking electronic microscopy and/or collagen-IV alpha-chains
immunofluresence study (COL-IF) (43.5%) during follow-up. With COL-IF as an additional criterion for AS diagnosis,
we found that patients with less than 3 criteria reached have increased risk of misdiagnosis (3.29-fold for all
misdiagnosed AS patients and 3.90-fold for fXLAS patients).
Conclusion: We emphasize timely and careful study of electronic microscopy and COL-IF in pathologic evaluation
of AS patients. With renal and/or skin COL-IF as additional criterion, 3 diagnosis criteria reached are the cutoff for
diagnosing AS pathologically.
Keywords: Alport syndrome, Diagnosis, Immunohistology, Renal biopsyBackground
Phenotypes of Alport syndrome (AS) exhibit a wide
spectrum of this systemic disorder of collagen IV mole-
cules, from mild clinical forms living to old ages to se-
vere forms developed into end stage renal disease early
in life [1-3]. The fundamental abnormalities lie in the
linear and/or the conformational structures of the sub-
chains of collagen IV molecules (COL-IV-α3:α4:α5 or
COL-IV-α5:α6:α5), caused by different individual geno-
types involving a monogenic mutation in COL4A3, or
COL4A4, or COL4A5 genes [4-6]. The disease entity of* Correspondence: yaoxd@hotmail.com
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reproduction in any medium, provided the orAS was first delineated clinically by A. Cecil Alport in
1927 as “a dominantly inherited hereditary nephritis”
characterized by hematuria and nerve deafness, affecting
both the male and the female members of the family [2].
The characteristic ophthalmologic changes found in
1950s [7,8], the widespread ultra-structural changes of
glomerular basement membrane (GBM) described in
1970s [9,10], and collagen-IV α-chain immunofluores-
cence (COL-IF) defects discovered in 1980s [11,12]
made histological diagnosis of the disease more accurate,
and the modes of inheritance discernable. After 1990s,
genotyping added still more accuracy to the diagnosis
and family counseling of AS, and nowadays, genotyping. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Alport syndrome [13,14].
However, despite these advances in understanding
AS, the histology of renal biopsy (and skin biopsy for
X-linked AS) still remain important in the initial
evaluation of most patients suspected with hereditary
nephritis, especially when renal manifestations are
present. Difficulties still exist in the pathologic diagno-
sis in AS patients [15] and misdiagnosis remains a
common event even after comprehensive clinical and
pathologic evaluation. Both pediatricians and nephrolo-
gists are confronted with difficult situations in which a
misdiagnosis was made in AS patients who previously
underwent a renal biopsy and were then treated for
other diseases. Previous studies have not addressed the
risk factors for initial misdiagnosis or the data neces-
sary to correct the diagnosis later.Table 1 Demographic data, clinical manifestation, and diagno
subgroups a
Variable Initially misdiagnosed gr
Total mXLAS fXLAS
Case number 52 17 23
Sex (male/female) 22/30 - -
Age (years)
At presentation 21.3 ± 12.8 20.1 ± 12.0 24.2 ± 14
At misdiagnosis 23.4 ± 12.5 20.2 ± 11.0 27.7 ± 13
At final diagnosis 27.6 ± 12.6* 24.9 ± 12.0 31.6 ± 13
Clinical manifestation
Hematuria alone 5 0 5
With proteinuria (>0.4 g/day) 17 4 6
With hypoalbuminemia (<35 g/L) 17 6 8
With CKD 3+ (eGFR <60 mL/min) 12 7 4
Specific diagnostic criteria
Positive family history (proband) 39 13 18
Renal/skin collagen 30*b 14 11*
Electron microscopic changes 30**c 10 9**
High tone deafness 10* 6* 3
Ocular defect 11 3 5
Non-specific diagnostic clues
Glomerular sclerosis 24 9 9
Interstitial foam cell 30 11 9
Thickness of Bowman capsule 45 17 17
Immunofluorescence paucity 38 14 15
Progressive proteinuria 37 15 11
Progressive hypoalbuminemia 28 12 9
a mXLAS, male X-linked Alport syndrome; fXLAS, female X-linked Alport syndrome; A
b Chi-squared test, p < 0.05.
c Chi-squared test, p < 0.01.To fill this gap, we conducted a retrospective study
comparing initially diagnosed and previously misdiag-
nosed AS patients using data collected in the China AS
Treatments and Outcomes Registry (CASTOR) e-sys-
tem. We identified the reasons for misclassification of
pathology in the previously misdiagnosed patients, and
the information used to correct the diagnosis later. Odds
ratios for misdiagnosis were analyzed in AS patients of
different inheritance modes, and diagnostic criteria for
AS discussed including COL-IF studies.
Methods
Patients
This study involved 104 Chinese patients with AS whose
data were collected in the CASTOR e-system (designed
and maintained in the Research Institute of Nephrology
in Nanjing, China). Among them, 52 cases had an initialstic parameters in Alport syndrome patient groups and
oup Initially correctly diagnosed group
ARAS Total mXLAS fXLAS ARAS
12 52 17 23 12
5/7 23/29 - - 6/6
.0 17.3 ± 10.9 18.9 ± 12.3 14.6 ± 12.4 18.6 ± 11.4 25.3 ± 11.9
.6 19.7 ± 10.5
.5* 24.0 ± 10.2 22.0 ± 11.2 19.4 ± 10.3 21.4 ± 11.8 26.8 ± 10.5
0 7 0 7 0
7 18 4 10 4
3 18 9 4 5
1 9 4 2 3
8 37 11 19 7
5* 43 16 17 10
11 45 12 22 11
1* 24 13 4 7
3 6 1 1 4
6 19 8 6 5
10 31 13 10 8
11 46 16 18 12
9 43 16 16 11
11 35 15 10 10
7 18 10 2 6
RAS, autosomal recessive Alport syndrome.
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during the last fifteen years in Mainland China. As con-
trols, 52 patients were selected whose diagnosis of AS
was accurately made on their first renal biopsy between
2001 and 2010 at the Research Institute of Nephrology
in Nanjing. These two groups were matched by inherit-
ance modes. General demographic data, clinical manifes-
tations and diagnosis related parameters in the two
groups are listed in Table 1.
In the misdiagnosis group, a treatment regime had
been designed for every patient and carried out or
followed-up for at least six months according to the mis-
diagnosis of the biopsy. These patients were followed as
out-patients by nephrologists in the Institute or were re-
ferred to the Institute for further evaluation. Correction
of diagnosis was made for every patient utilizing the
diagnostic criteria and the procedures described below.
Diagnostic criteria of alport syndrome
Every patient in this study underwent a renal biopsy ei-
ther during the initial evaluation or later re-evaluation.
Diagnostic criteria for AS applied in this study included
the following five specific criteria, with at least three
required to establish the diagnosis. These are based on
the classic criteria presented by Flinter [15].
1. Typical or atypical electronic microscopic (EM)
change of GBM in renal biopsy.
2. Typical or atypical COL-IF changes observed in renal
and/or skin biopsy.
3. A family member as proband whose diagnosis was
based on evidence of EM and/or COL-IF in renal/
skin biopsy, or on a detailed family history of an X-
linked mode or of autosomal recessive inheritance
(defined as consanguineous parents or both parents
with hematuria).
4. Definite evidence of high-tone deafness, in both ears,
with or without clinical deafness.
5. Definite evidence of a lens abnormality( anterior or
posterior lenticonus) and/ or flecks in the peripheral
or mid-peripheral rentina area [16].
Diagnostic clues included non-specific pathologic
changes and clinical characteristics that are of diagnostic
value, but not required as diagnostic criteria. These
included globular/segmental glomerular sclerosis, inter-
stitial foam cell clustering, Bowman’s capsule wall thick-
ness, a pauci-immune pattern of deposits in routine
immunoflurence, progressive proteinuria and progressive
hypoalbuminemia.
Renal and skin pathology
Percutaneous renal biopsy was performed in every
patient during the initial evaluation. A second renalbiopsy was performed for those referred patients whose
data or samples for EM or immunofluorescence studies
were not available. Handling of renal and skin biopsy
samples has been described in previous reports [17].
Re-examination of biopsy slides in atypical cases is
facilitated by the CASTOR e-system in China which
is easily accessible to pathologists and nephrologists
concerned [18].
Correction procedures
To correct misdiagnosis, procedures used included refer-
ence to proband later diagnosed pathologically, first
renal biopsy slides re-evaluation, a second renal biopsy
with completed evaluation (including EM and COL-IF),
skin biopsy for collagen IV a-5 chain immunoflurence
study, and ruling out of coexisted morbidities (including
hepatitis B virus infection, Henoch-Shönlein purpura,
primary hypertension, obesity and drug-induced tubu-
lointerstitial damages).
Statistical analysis
SPSS 16.0 was used for the statistical analysis. Baseline
characteristics of patients in each AS type were com-
pared by using the chi-squared test for categorical vari-
ables. Data are presented as the mean ± standard
deviations for continuous variables and as numbers and
proportions for categorical variables. To identify the pre-
dictors of misdiagnosis risk, the number of diagnosic cri-
teria reached was treated as a dichotomous variable (<3
vs. 3+). Logistic regression was performed to conduct
univariate and multivariate analysis. All tests were two-
sided. A p-value of <0.05 was considered significant.
Results
Patients’ general data
This cohort of misdiagnosed patients represents 13% of
the 398 patients whose data are completely retrieved in
the CASTOR e-system. Table 1 lists general characteris-
tics, clinical manifestations, specific diagnostic criteria
reached and non-specific diagnostic clues in the two
groups. There was no significant difference in average
age at presentation between the two groups or among
the subgroups. A difference of significance was found in
the average age at final diagnosis between the two
groups and between the two female XLAS subgroups
(both p < 0.05). Differences of significance were also
found between the percentages of specific criteria by EM
(p < 0.01) and COL-IF (p < 0.05) in the two female XLAS
sub-groups. Male XLAS patients in the control group
had a higher rate of detected high-tone sensorineural
deafness (p < 0.05). No significant difference was found
in any of the other diagnostic parameters between the
two groups.
Table 2 Misclassifications of pathology in the initially misdiagnosed groupa
Corrected diagnosis Previous misdiagnosis N % in subgroup % in whole group
fXLAS 23 44.2
FSGS 8 34.8 15.4
MsPGN 5 21.7 9.6
IgAN (mesangial proliferation) 4 17.4 7.7
TBMN 3 13.0 5.8
MCD 2 8.7 3.8
IgMN 1 4.3 1.9
mXLAS 17 32.7
MsPGN 7 41.2 13.5
IgAN (MsP) 2 11.8 3.8
IgAN (with FGS) 2 11.8 3.8
IMN 2 11.8 3.8
FSGS 2 11.8 3.8
HTN 1 5.9 1.9
D_TIN 1 5.9 1.9
ARAS 12 23.1
MCD 2 16.7 3.8
MsPGN 2 16.7 3.8
MN 2 16.7 3.8
IgAN (mesangial proliferation) 1 8.3 1.9
TBMN 1 8.3 1.9
IgM nephropathy 1 8.3 1.9
MPGN 1 8.3 1.9
Pregnancy related nephropathy 1 8.3 1.9
Obesity related nephropathy 1 8.3 1.9
aFSGS, focal segmental glomerulosclerosis; MsPGN, mesangial proliferative glomerulonephritis; IgAN, IgA nephropathy; TBMN, thin basement membrane
nephropathy; MCD, minor change disease; IMN, idiopathic membranous nephropathy; HTN, hypertensive nephropathy; D-TIN, drug-induced tubulointerstitial
nephritis; MPGN, membranous proliferative glomerulonephritis.
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In Table 2 the incorrect biopsy diagnosis is shown in
subgroups of different modes of inheritance. Diffuse
mesangial proliferation are predominant in both groups,
while female XLAS patients were more likely to be mis-
diagnosed as focal segmental glomerulonephritis, with
some patients found to have immunoglobulin A and/or
immunoglobulin M deposits, atypical membranous
changes, prominent tubulointerstial changes and ische-
mic vascular changes.
Correction procedures
For each patient in the misdiagnosis group, one major
finding and one or more minor findings were utilized to
correct the diagnosis. Different major findings were used
more often in different subgroups (Table 3). In female
XLAS patients the diagnosis was frequently corrected
after a family member was diagnosed or when re-
examination of previous biopsy slides confirmed thepresence of atypical changes in both EM and COL-IF
studies. The correct diagnosis in male XLAS patients
and in ARAS patients usually resulted from a second
renal biopsy that included complete evaluation in both
EM and COL-IF studies.Risks for misdiagnosis
In order to identify factors which increased the risk of
misdiagnosis, logistic regression was used (Table 4). The
presence of three or more diagnostic criteria was used as
the reference. The presence of less than 3 diagnostic cri-
teria increased the risk of misdiagnosis 3.29-fold in all
patients and 3.90 fold in female XLAS patients respect-
ively. Even when a pathologically diagnosed proband was
present in the family, the risk of misdiagnosis when less
than 3 pathologic criteria were present still remained
3.82 for female XLAS patients and 3.27 for the whole
group. The presence of at least three diagnostic criteria
Table 3 Procedures for the correction of pathologic misdiagnosis in previously diagnosed group
Subtypes Primary procedures N Secondary procedures N
fXLAS Correction after proband diagnosed 8 plus skin biopsy 3
plus recheck of EM 5
later found FH 6
rule out confounding factors 2
later developed ear/eye damage 1
Recheck of EM/COL in renal tissue during follow-up 10 recheck EM in renal tissue 8
recheck kidney collagen stain 2
Renal re-biopsy with EM/COL exams 3 rule out confounding factors 2
plus skin biopsy 1
Skin biopsy alone 2
mXLAS Correction after proband diagnosed 1 plus skin biopsy 1
Renal re-biopsy with EM/COL 13 plus skin biopsy 12
later found FH 5
Skin biopsy alone 3 later developed ear/eye damage 2
plus recheck of EM/COL 3
ARAS Renal re-biopsy with EM/COL exams 8 later found FH 6
rule out confounding factors 4
Recheck EM/COL exams in renal tissue 3 later found FH 1
Proband 1 later found FH 1
N, patients number; mXLAS, male patients with X-linked Alport syndrome; fXLAS, female patients with X-linked Alport syndrome; ARAS, autosomal recessive Alport
syndrome FH, positive family history; EM, electronic microscopy; COL,collagen-IV immunofluorescence.
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in these patients evaluated with renal biopsy.
Discussion
The diagnosis of AS can be difficult because of the wide
spectrum of both clinical and pathologic phenotypes
that are seen [19,20]. Diagnosis in an adult patient is less
difficult than in children because progression has usually
occurred, making other diagnoses less likely. However,
even in adults accurate diagnosis can be difficult, be-
cause of later-onset phenotypes, non-specific renal man-
ifestations complicated by other coexistent morbidities,
prominent non-specific light microscopic findings. This
was especially true when family history were not easily
available or changes of EM and COL-IF were atypical or
not available[20].Table 4 Predicting misdiagnosis risk by number of diagnostic
AS
Type
N Diagnostic criteria reached
< 3 components 3+ compone
Total 104 46 58
fXLAS 46 20 26
mXLAS 34 15 19
ARAS 24 11 13
a AS, Alport syndrome; fXLAS, female X-linked Alport syndrome; mXLAS, male X-linke
ratio. L for two sides analysis, and U for single side analysis.Table 2 shows the percentages of patients misdiag-
nosed with different inheritance modes and the incorrect
diagnoses they received. About 11% of AS patients with
renal pathology data retrieved in the CASTOR e-system
were previously misdiagnosed: 27.7% in female XLAS,
17.7% in ARAS, and 6.9% in male XLAS patients. The
Patients included in the present study were adolescent
or adult, evaluated at an average age of about 20 years,
suggesting some were in a late-onset subgroup. In the
previously misdiagnosed group, there was a 4-year inter-
val between the misdiagnosis and the correction. This
study did not include patients of autosomal-dominant
mode because of the small number of cases and the un-
certainty of inheritance mode determination.
Renal manifestations at initial evaluation did not differ
between the misdiagnosed group and the diagnosedcriteria reached and types a
< 3 vs. 3+
nts OR 95L 95U p value
3.29 1.42 7.60 0.005
3.90 0.96 15.89 0.057
2.20 0.51 9.49 0.291
2.37 0.37 15.19 0.363
d Alport syndrome; ARAS, autosomal recessive Alport syndrome; OR, odds
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different, later evaluations were associated with the pre-
viously misdiagnosed group, especially female XLAS
patients. Comparison of non-renal manifestations be-
tween the two groups shows that XLAS patients in the
group promptly diagnosed correctly were more typical,
because of more male XLAS patients with sensorineural
deafness and more female XLAS patients with typical
EM and COL-IF changes (see Table 1).
The misdiagnoses identified in this cohort of patients
were often a reflection of histological misclassification
based primarily on light microscopic findings, and fail-
ure to perform or accurately interpret EM and collagen
IV studies [18,21]. Light microscopy is widely regarded
as of limited value for differentiating between primary
glomerulonephritis and AS [22,23]. Diffuse mesangial
proliferative changes were observed in most AS patients
(ARAS patients and all male XLAS and young female
XLAS patients). Segmental changes (either segmental
proliferation or focal global/segmental glomerulosclero-
sis) were more frequently found in advanced AS patients
and female XLAS patients [24,25].
We did not find significant differences between the
two groups with respect to the presence of non-specific
diagnostic lesion, including basement membrane thick-
ness in GBM or Bowman’s capsule, foam cell clustering
in the interstitium, and pauci-immune feature in routine
immunoflurence studies. Non-specific immune deposits
were observed in a few patients, but more specific pat-
terns of deposition were observed only in those with
coexisting renal conditions, such as primary IgA nephro-
pathy, idiopathic membranous nephropathy, lupus neph-
ritis, diabetes, primary hypertension, hepatitis B virus
infection, pregnancy-related nephropathy, and drug-
induced tubulointerstitial nephritis. More difficulties in
diagnosis were found in female XLAS patients, with fre-
quent misclassification as focal segmental glomerulo-
sclerosis, mesangial proliferative glomerulonephritis,
minimal change disease, and thin basement membrane
nephropathy.
The procedures used to correct the diagnosis in mis-
diagnosed patients are described in Table 2 with one pri-
mary procedure, with or without secondary procedures.
Re-biopsy with complete evaluation of EM and COL-IF
was the most frequently used procedure for correcting
the diagnosis in male XLAS patients and ARAS patients
whose family history was atypical or difficult to obtain,
and whose first biopsy samples were not available for
EM and COL-IF studies.
Most re-biopsied patients were referred patients with-
out data of EM and COL-IF studies in their initial biopsy
performed in local hospitals. Re-biopsy usually showed
typical changes in both EM and COL-IF studies, as
well as more prominent non-specific lesion (includingthickened GBM and laminated Bowman’s capsule and
more severe clustering of interstitial foam cells). Skin bi-
opsy for collagen IVα5-chain immunofluorescence study
is complementary in diagnosing XLAS, although it may
be less sensitive in female patients [26,27]. Early stage
AS patients may present as thin basement membrane
disease, with or without messangial lesion. This is espe-
cially common in female XLAS patients, in ARAS
patients, or AS patients with compounded mutations in
COL4A3 and COL4A4. Progression of renal lesion from
thin basement membrane disease to focal and segmental
glomerular sclerosis has been observed and reported in
both XLAS patients and ARAS patients diagnosed with
genotyping [24].
Diagnostic criteria for AS were first presented by Flin-
ter and colleagues in 1988 and were widely accepted
during the years followed for a clinico-pathologic diag-
nosis [15]. Efforts have been made to include genotyping
and COL-IF study as more specific diagnostic criteria,
and more patients from AS families are thus diagnosed
without resort to renal biopsy. Over the last 20 years
when renal biopsy played an essential role in the initial
evaluation of AS patients, genotyping has been accepted
as a gold standard in AS diagnosis and family counseling
worldwide, with the growing availability of the technique
to clinic. Typical EM changes in GBM are considered as
pathologically specific in patients evaluated with renal
biopsy, and COL-IF studies (of renal and/or skin sam-
ples) are accepted as molecularly accurate diagnostic cri-
teria besides genotyping for AS diagnosis [28-31].
Family history is also an important clue leading to dir-
ect work-up with planned order for COL-IF testing at
initial evaluation. However, in our study, difficulties
existed in collecting family history data in both the mis-
diagnosed and the promptly diagnosed groups. There
were 13 patients (25%) in the misdiagnosed group and
15 patients (28.8%) in the promptly diagnosed group
whose family history was negative or atypical. Family
history may be absent in patients with de-novo muta-
tions, or atypical in patients from small size families, or
may be difficult to obtain for cultural and social reasons.
There were 26 patients in the previously misdiagnosed
group whose family histories were discovered only dur-
ing the second evaluation with renal biopsy or during
long term follow-up after the first evaluation. In 8 fe-
male XLAS patients, positive family history was available
only after a family member was later diagnosed with
pathologic evidence of AS, which was important for cor-
rection of previous misdiagnosis in these patients [32].
Difficulties also existed in evaluating both the EM and
the COL-IF studies. Thick and splitting GBM under EM
is the most typical diagnostic feature before genotyping
is conducted, but there were several cases in which
changes of thin basement membrane nephropathy and
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[19]. Attenuated staining with monoclonal antibodies for
the sub-chains of collagen IV has been found in some
patients who manifested atypical in COL-IF studies. In
clinical practice, delayed reports, inadequate biopsy sam-
pling, technique failure, and unavailable facilities for
complete studies in some hospitals frequently contribu-
ted to misdiagnosis. In female XLAS patients and
younger patients, the EM and COL-IF changes might be
even more atypical and easily overlooked [33].
Although changes by light microscopy alone are not
specific for the diagnosis of AS, important pathologic
clues included pauci-immune deposits associated with
minor glomerular change, thick or laminated walls of ca-
pillary and Bowman’s capsule, clustered foam cells in
interstitial area that should remind pathologists and
nephrologists of the possibility of the syndrome and the
need for timely EM and COL-IF studies plus clinical
evaluation of ears and eyes [16,34-36]. Non-specific clin-
ical clues such as progressive proteinuria and sustained
hypoalbuminemia were frequently observed in long-term
follow-up and also used as clues to correct misdiagnosis
[37,38].
In practice, there is usually a period of days or weeks
for collecting diagnostic data for AS. Even after evalu-
ation of the renal biopsy in some patients, there is a
“mid-diagnosis” period for further investigation of family
history, for waiting the EM report, for further study of
collagen IV chains in renal biopsy or further ordering of
skin biopsy, and/or for a genotyping study of the family.
In the misdiagnosed group, patients previously misdiag-
nosed as thin basement membrane nephropathy had this
period of mid-diagnosis.
Including COL-IF as an additional diagnostic criterion,
we analyzed the number of reached criteria and the odds
ratio of misdiagnosis. We found that AS patients with
fewer than three diagnostic criteria had a 3.29-fold risk
for misdiagnosis, and the OR reached 3.90 in female
XLAS patients (Table 4).
In China, more and more hospitals and institutions are
able to perform renal biopsy and routine pathologic evalu-
ation. However, there remains a great need for cooper-
ation and development, including a better referral system
to share pathologic and genetic information [37-39]. The
CASTOR e-system was developed for this purpose and to
facilitate better care of AS patients in China. Collabor-
ation through an effective e-system will not only reduce
the chance of misdiagnosis but also provide a good
research platform for AS treatment studies [40-43].
This study has several limitations. First, it did not
cover young children, and the patients involved were of
adults and adolescents, thus increasing the proportion of
patients classified as late onset subtypes. Second, it did
not directly analyze the factors leading to misdiagnosisbecause these direct data of the referred patients were
often not available. Third, most of the patients were not
diagnosed with genotyping. The information provided in
this study indicates that (a) to minimize the chance of
misdiagnosis in AS, patient’s data on the five specific
parameters listed above must be obtained initially, and
(b) atypical cases (especially female XLAS patients) with
less than 3 of these diagnostic criteria are at greater risk
for misdiagnosis.
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